Bernstein Liebhard LLP has announced the filing of a shareholder class action lawsuit against Corcept Therapeutics Incorporated (CORT), alleging the company made material misrepresentations regarding clinical evidence supporting its drug relacorilant. Shareholders who purchased company stock during specified periods may be eligible to participate in the litigation and are encouraged to contact the firm to discuss their legal rights and potential remedies.
The lawsuit represents one of three shareholder actions announced by the firm, alongside separate cases against Zynex and NuScale Power. Class action litigation of this nature typically addresses allegations that companies failed to disclose material information or made false statements that impacted share prices. Eligible investors are those who acquired shares during the class period and experienced losses as a result of the alleged misstatements.
Investors with significant losses in Corcept Therapeutics shares are being urged to reach out to Bernstein Liebhard LLP to evaluate their participation in the case. The firm specializes in securities litigation and shareholder disputes, and legal consultation regarding class action eligibility is typically available at no upfront cost to potential plaintiffs.